Literature DB >> 18267248

L-DOPA-induced dyskinesia: cellular mechanisms and approaches to treatment.

M Angela Cenci1.   

Abstract

L-DOPA-induced dyskinesia (LID) is a common complication of the treatment of Parkinson's disease, and its precise mechanisms have long remained unknown. Rodent models of LID provide a tool to dissect the impact of specific factors on the development and expression of dyskinetic movements. This short review will summarize recent findings from rodent studies that have consolidated and considerably expanded our mechanistic understanding of LID. Based on the experimental findings, the review will propose a chart of possible treatment options acting on different pathophysiological levels.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18267248     DOI: 10.1016/S1353-8020(08)70014-2

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  14 in total

1.  Effects of the beta-adrenergic receptor antagonist Propranolol on dyskinesia and L-DOPA-induced striatal DA efflux in the hemi-parkinsonian rat.

Authors:  Nirmal Bhide; David Lindenbach; Christopher J Barnum; Jessica A George; Margaret A Surrena; Christopher Bishop
Journal:  J Neurochem       Date:  2015-04-27       Impact factor: 5.372

2.  Late aging-associated increases in L-DOPA-induced dyskinesia are accompanied by heightened neuroinflammation in the hemi-parkinsonian rat.

Authors:  Kathryn Lanza; Amy E Perkins; Terrence Deak; Christopher Bishop
Journal:  Neurobiol Aging       Date:  2019-05-31       Impact factor: 4.673

Review 3.  Contribution of serotonergic transmission to the motor and cognitive effects of high-frequency stimulation of the subthalamic nucleus or levodopa in Parkinson's disease.

Authors:  Sylvia Navailles; Philippe De Deurwaerdère
Journal:  Mol Neurobiol       Date:  2012-01-06       Impact factor: 5.590

4.  The effects of BMY-14802 against L-DOPA- and dopamine agonist-induced dyskinesia in the hemiparkinsonian rat.

Authors:  Nirmal Bhide; David Lindenbach; Margaret A Surrena; Adam A Goldenberg; Christopher Bishop; S Paul Berger; Melanie A Paquette
Journal:  Psychopharmacology (Berl)       Date:  2013-02-07       Impact factor: 4.530

Review 5.  Preclinical assessment of stem cell therapies for neurological diseases.

Authors:  Valerie L Joers; Marina E Emborg
Journal:  ILAR J       Date:  2009

6.  Imbalanced Dopaminergic Transmission Mediated by Serotonergic Neurons in L-DOPA-Induced Dyskinesia.

Authors:  Sylvia Navailles; Philippe De Deurwaerdère
Journal:  Parkinsons Dis       Date:  2011-10-11

7.  Striatal molecular signature of subchronic subthalamic nucleus high frequency stimulation in parkinsonian rat.

Authors:  Sylviane Lortet; Emilie Lacombe; Nicolas Boulanger; Pascal Rihet; Catherine Nguyen; Lydia Kerkerian-Le Goff; Pascal Salin
Journal:  PLoS One       Date:  2013-04-04       Impact factor: 3.240

8.  NMDA receptor regulation of levodopa-induced behavior and changes in striatal G protein-coupled receptor kinase 6 and β-arrestin-1 expression in parkinsonian rats.

Authors:  Na Wu; Lu Song; Xinxin Yang; Weien Yuan; Zhenguo Liu
Journal:  Clin Interv Aging       Date:  2013-03-26       Impact factor: 4.458

9.  Effect of Tianqi antitremor granules on behavioral manifestations and expression of G protein-coupled receptor kinase 6 and β-arrestin1 in levodopa-induced dyskinesia in a rat model of Parkinson's disease.

Authors:  Na Wu; Xinxin Yang; Lu Song; Jianglei Wei; Zhenguo Liu
Journal:  Drug Des Devel Ther       Date:  2013-12-10       Impact factor: 4.162

10.  Pioglitazone ameliorates the phenotype of a novel Parkinson's disease mouse model by reducing neuroinflammation.

Authors:  Milena Pinto; Nadee Nissanka; Susana Peralta; Roberta Brambilla; Francisca Diaz; Carlos T Moraes
Journal:  Mol Neurodegener       Date:  2016-04-02       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.